http://orcid.org/0000-0002-1559-2868
References
- Bae EY, Lee EK. Pharmacoeconomic guidelines and their implementation in the positive list system in South Korea. Value Health: Journal International Society Pharmacoeconomics Outcomes Research. 2009;12(Suppl 3):S36–41.
- Bae EY, Hong JM, Kwon HY, et al. Eight-year experience of using HTA in drug reimbursement: South Korea. Health Policy (New York). 2016;120(6):612–620.
- Charokopou M, Majer IM, Raad J, et al. Which factors enhance positive drug reimbursement recommendation in Scotland? A retrospective analysis 2006-2013. Value Health: Journal International Society Pharmacoeconomics Outcomes Research. 2015;18(2):284–291.
- Lee JYCY, Kim ST, Kim SJ. Methods on improvement of accessibility for rare disease treatments: providers’ perspective. Korean Assoc Health Technol Assess. 2014;2(1):35–42.
- Bae EY. Positive list system in korea: issues and challenges. Korean Assoc Health Technol Assess. 2013;1:43–50.
- Cheong CLLTJ, Son KB, Bae EY. Risk sharing agreements on pharmaceuticals: lessons from foreign countries’ experience. Korean Assoc Health Technol Assess. 2013;1:51–60.
- Park SE, Lim SH, Choi HW, et al. Evaluation on the first 2 years of the positive list system in South Korea. Health Policy (New York). 2012;104(1):32–39.
- Ministry of Health and Welfare Press release. Development Strategy of New drug’s pricing policy. Available at http://www.mohw.go.kr/front_new/al/sal0301vw.jsp?PAR_MENU_ID=04&MENU_ID=0403 [accessed 06.30.16]. (2016).
- Ha D, Choi Y, Kim DU, et al. A comparative analysis of the impact of a positive list system on new chemical entity drugs and incrementally modified drugs in South Korea. Clin Ther. 2011;33(7):926–932.
- Yang BM. The future of health technology assessment in healthcare decision making in Asia. Pharmacoeconomics. 2009;27(11):891–901.
- Health Insurance Review and Assessment Service. Detail Evaluation Criteria for drugs subject to negotiation including new drugs, etc. Available at http://www.hira.or.kr/dummy.do?pgmid=HIRAA020002000000&cmsurl=/cms/inform/01/1351466_27106.html&subject=%e3%80%8c%ec%8b%a0%ec%95%bd+%eb%93%b1+%ed%98%91%ec%83%81%eb%8c%80%ec%83%81+%ec%95%bd%ec%a0%9c%ec%9d%98+%ec%84%b8%eb%b6%80%ed%8f%89%ea%b0%80%ea%b8%b0%ec%a4%80%e3%80%8d+%ec%9d%bc%eb%b6%80%ea%b0%9c%ec%a0%95%282016.10.%29. 2016.
- Ministry of Health and Welfare. Criteria for decision or adjustment on drugs (MOHW notification No. 2015-80). Available at http://www.mohw.go.kr/front_new/jb/sjb0406vw.jsp?PAR_MENU_ID=03&MENU_ID=030406&CONT_SEQ=322636&page=1. 2015.
- Health Insurance Review and Assessment Service. Regulation for evaluation criteria and procedure for reimbursement of drug. Available at http://www.hira.or.kr/dummy.do?pgmid=HIRAA040055000000 [accessed 06.30.16]. (2016).
- National Health Insurance Service, Guideline to drug-pricing negotiation. Available at http://www.nhis.or.kr/menu/retriveMenuSet.xx?menuId=D6000 [accessed 06.30.16]. (2016).
- Dakin HA, Devlin NJ, Odeyemi IA. “Yes”, “No” or “Yes, but”? Multinomial modelling of NICE decision-making. Health Policy (New York). 2006;77(3):352–367.
- Harris AH, Hill SR, Chin G, et al. The role of value for money in public insurance coverage decisions for drugs in Australia: a retrospective analysis 1994-2004. Medical Decision Making: an International Journal of the Society for Medical Decision Making. 2008;28(5):713–722.
- Linley WG, Hughes DA. Reimbursement decisions of the all wales medicines strategy group: influence of policy and clinical and economic factors. Pharmacoeconomics. 2012;30(9):779–794.
- Cerri KH, Knapp M, Fernandez JL. Public funding of pharmaceuticals in The Netherlands: investigating the effect of evidence, process and context on CVZ decision-making. European Journal Health Economics: HEPAC: Health Economics Prevention Care. 2014;15(7):681–695.
- Cerri KH, Knapp M, Fernandez JL. Decision making by NICE: examining the influences of evidence, process and context. Health Econ Policy Law. 2014;9(2):119–141.
- Picavet E, Cassiman D, Simoens S. Reimbursement of orphan drugs in Belgium: what (else) matters?. Orphanet J Rare Dis. 2014;9:139.
- Ministry of Food and Drug Safety, Regulation of orphan drug designation. Available at http://www.mfds.go.kr/index.do?x=0&searchkey=title:contents&mid=686&searchword=희귀의약품&y=0&division=&pageNo=1&seq=10666&sitecode=2016-05-12&cmd=v. 2016.
- Kalo Z, Annemans L, Garrison LP. Differential pricing of new pharmaceuticals in lower income European countries. Expert Rev Pharmacoecon Outcomes Res. 2013;13(6):735–741.
- Remuzat C, Urbinati D, Mzoughi O, et al. Overview of external reference pricing systems in Europe. Journal Market Access Health Policy. 2015;3:27675. http://dx.doi.org/10.3402/jmahp.v3.27675.
- KRPIA. Proposals for improving patient access to new prescription pharmaceuticals in Korea. Available at: http://www.krpia.or.kr/bbs/bbs_view.asp?num=14304„gubun=21 [accessed 12.17.16] (2016)
- Cheema PK, Gavura S, Migus M, et al. International variability in the reimbursement of cancer drugs by publically funded drug programs. Curr Oncology. 2012;19(3):e165–176.